Track topics on Twitter Track topics that are important to you
Key opinion leaders from industry, academia, medical research centers and the investment community gather to bridge business, clinical and scientific aspects of immuno-oncology to transform the way cancer is treated.
New York, NY (PRWEB) December 01, 2016
The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° (IO360°) event is expanding to three days and will take place on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated.
“We are undergoing a radical change in cancer treatment and the biopharma industry needs to gain information that will be beneficial for industry and patients,” said Dr Hoos. “The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have in clinical designs and recruitment procedures.”
The conference will feature keynote addresses on “Clonal Selection of Neo-Antigen Biology” led by Dr Sergio Quezada (University College London Cancer Institute); “Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures,” led by Dr James Allison (MD Anderson Cancer Center); and “A Melanoma Survivor Story: T.J. Sharpe’s Immunotherapy Trial Journey,” led by T.J. Sharpe (Melanoma Survivor, Advocate and Cancer Blogger). In addition to the keynotes, the conference has plenary sessions designed around:
IO360° is supported through partnerships with The Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), the Patient Empowerment Network (PEN) and the Society of Immunotherapy for Cancer (SITC).
“With the support of CRI, SITC, PEN and CIMT, the IO360° program will help drive the field of cancer immuno-therapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated,” said Kate Woda, Conference Director.
The speaking faculty at IO360° 2017 includes:
The Immuno-Oncology 360° program provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. IO360° is located at The Roosevelt Hotel, New York City, NY from February 1 - 3, 2017. For more information, visit here or go to http://theconferenceforum.org/
About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. The company examines and challenges the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also presents PharmaTalkRadio with free podcasts for the life science industry and patient advocacy. For more information, visit http://theconferenceforum.org/
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/12/prweb13893228.htmNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...